Regeneron to Submit Application for Cemdisiran in Myasthenia Gravis Following Positive Phase 3 NIMBLE Data
Regeneron's cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.